Lucas Gallo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucas Gallo has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Achilleas Thoma
McMaster University
18 shared publications - Sophocles H. Voineskos
University of Toronto
14 shared publications - Patrick Kim
McMaster University
13 shared publications - Christopher J. Coroneos
McMaster University
9 shared publications - Morgan Yuan
University of Toronto
9 shared publications - Charlene Rae
Department of Pediatrics McMaster University Hamilton Ontario Canada
8 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
Rapid Identification of Low-Quality Meta-Analyses in Plastic Surgery Using the Meta-Analysis Critique (MAC) Tool
Meta-analyses provide the highest level of evidence within academic health literature. However, they vary significantly in quality and bias. Existing methodological assessment tools for meta-analyses are often time consuming and difficult for clinicians to use. The Meta-analysis Critique (MAC) tool was developed as a simple 3-question screening instrument designed to quickly appraise study quality. In this study, temporal trends and correlations between the MAC tool and AMSTAR 2 (the current gold standard) were analyzed. MEDLINE and Embase were searched for plastic surgery meta-analyses published between 2011 and 2023, and 283 studies were identified. These were independently assessed by 2 reviewers using both AMSTAR 2 and the MAC tool. While the volume of meta-analyses in plastic surgery significantly increased in the latter half of the decade (n = 68 [24%] vs n = 215 [76%]), the proportion of high-quality studies did not improve. Compared to AMSTAR 2, the MAC tool obtained high specificities when assessing the research question (100.00%; 95% CI, 90.97%-100.00%), appropriateness of the statistical analysis (96.23%; 95% CI, 87.02%-99.54%), and risk of bias (98.97%; 95% CI, 94.39%-99.97%). This study presents a novel tool that simplifies assessment of plastic surgery literature and identifies poor-quality meta-analyses but is not intended as a confirmatory quality-assessment instrument. The results obtained with the MAC tool show a strong correlation with the gold-standard AMSTAR 2. Future studies should aim to validate this tool and determine its broader reliability in other specialties.
- 31 July 2026
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
Open AccessRapid Identification of Low-Quality Meta-Analyses in Plastic Surgery Using the Meta-Analysis Critique (MAC) Tool
Meta-analyses provide the highest level of evidence within academic health literature. However, they vary significantly in quality and bias. Existing methodological assessment tools for meta-analyses are often time consuming and difficult for clinicians to use. The Meta-analysis Critique (MAC) tool was developed as a simple 3-question screening instrument designed to quickly appraise study quality. In this study, temporal trends and correlations between the MAC tool and AMSTAR 2 (the current gold standard) were analyzed. MEDLINE and Embase were searched for plastic surgery meta-analyses published between 2011 and 2023, and 283 studies were identified. These were independently assessed by 2 reviewers using both AMSTAR 2 and the MAC tool. While the volume of meta-analyses in plastic surgery significantly increased in the latter half of the decade (n = 68 [24%] vs n = 215 [76%]), the proportion of high-quality studies did not improve. Compared to AMSTAR 2, the MAC tool obtained high specificities when assessing the research question (100.00%; 95% CI, 90.97%-100.00%), appropriateness of the statistical analysis (96.23%; 95% CI, 87.02%-99.54%), and risk of bias (98.97%; 95% CI, 94.39%-99.97%). This study presents a novel tool that simplifies assessment of plastic surgery literature and identifies poor-quality meta-analyses but is not intended as a confirmatory quality-assessment instrument. The results obtained with the MAC tool show a strong correlation with the gold-standard AMSTAR 2. Future studies should aim to validate this tool and determine its broader reliability in other specialties.
- Open Access
- 15 May 2026
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
Measuring Facial Appearance in the Era of GLP-1 Receptor Agonist Use With the FACE-Q Aesthetics Item Library
Background: A patient-reported outcome measure is needed to study facial appearance in the context of rapid weight loss following use of antiobesity medications. Such treatments can cause sunken cheeks, hollow eyes, saggy skin, and an aged appearance (eg, Ozempic face). The FACE-Q Aesthetics item library can be used to create short-form fit-for-purpose scales. Objectives: The goal was to create a short-form FACE-Q scale and to examine its psychometric performance in the context of antiobesity medication use. Methods: An international sample (Prolific Academic) was surveyed 3 times (initial, test–retest, 3-month follow-up). The sample included individuals who wanted to have, were having, or previously had a glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist to lose weight. Participants completed the FACE-Q item library that measures satisfaction with facial appearance. Rasch Measurement Theory analysis was used to item-reduce and produce a short-form scale. Psychometric properties were examined, including hypothesis-based construct validity, responsiveness, and test–retest reliability. Distribution-based and anchor-based minimally important differences (MIDs) were computed. Results: The sample included 632 individuals who wanted to have (30.9%), were having (50.6%), or previously had (18.5%) a GLP-1 or GIP/GLP-1 receptor agonist to lose weight. Data for a 15-item short-form scale fit the Rasch model (χ2 = 130.1, df = 135, P = .60). Reliability was > 0.83 for 3 reliability coefficients. Hypothesis-based construct validity was supported with 14/14 (100%) and 7/9 (77.8%) of initial and change score hypotheses confirmed, respectively. The MIDs for the new scale for improvements were 6 (distribution-based) and 10 (anchor-based) points. Conclusions: This FACE-Q Aesthetics short-form scale demonstrated strong measurement properties in the context of GLP-1 and GIP/GLP-1 receptor agonist use for weight loss. Level of Evidence: 4 (Diagnostic):
- 15 May 2026
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
Open AccessMeasuring Facial Appearance in the Era of GLP-1 Receptor Agonist Use With the FACE-Q Aesthetics Item Library
Background: A patient-reported outcome measure is needed to study facial appearance in the context of rapid weight loss following use of antiobesity medications. Such treatments can cause sunken cheeks, hollow eyes, saggy skin, and an aged appearance (eg, Ozempic face). The FACE-Q Aesthetics item library can be used to create short-form fit-for-purpose scales. Objectives: The goal was to create a short-form FACE-Q scale and to examine its psychometric performance in the context of antiobesity medication use. Methods: An international sample (Prolific Academic) was surveyed 3 times (initial, test–retest, 3-month follow-up). The sample included individuals who wanted to have, were having, or previously had a glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist to lose weight. Participants completed the FACE-Q item library that measures satisfaction with facial appearance. Rasch Measurement Theory analysis was used to item-reduce and produce a short-form scale. Psychometric properties were examined, including hypothesis-based construct validity, responsiveness, and test–retest reliability. Distribution-based and anchor-based minimally important differences (MIDs) were computed. Results: The sample included 632 individuals who wanted to have (30.9%), were having (50.6%), or previously had (18.5%) a GLP-1 or GIP/GLP-1 receptor agonist to lose weight. Data for a 15-item short-form scale fit the Rasch model (χ2 = 130.1, df = 135, P = .60). Reliability was > 0.83 for 3 reliability coefficients. Hypothesis-based construct validity was supported with 14/14 (100%) and 7/9 (77.8%) of initial and change score hypotheses confirmed, respectively. The MIDs for the new scale for improvements were 6 (distribution-based) and 10 (anchor-based) points. Conclusions: This FACE-Q Aesthetics short-form scale demonstrated strong measurement properties in the context of GLP-1 and GIP/GLP-1 receptor agonist use for weight loss. Level of Evidence: 4 (Diagnostic):
- Open Access
- 18 March 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5) , 498-503
Responsiveness of the NAIL-Q Patient-Reported Outcome Measure
Background: Nail conditions account for ~10% of dermatological conditions and can significantly impact quality of life. The NAIL-Q is a patient-reported outcome measure that was developed to measure outcomes that matter to patients treated for any type of fingernail or toenail condition. The ability of the NAIL-Q to detect change (ie, responsiveness) has not yet been established. Objective: To evaluate the responsiveness of the NAIL-Q in patients undergoing treatment for nail psoriasis, onychomycosis, brittle nails, and retronychia. Methods: This prospective validation study included patients newly diagnosed at an urban dermatology clinic in the United States. Participants completed the NAIL-Q at baseline, 3, and 6 months. Responsiveness was evaluated by testing predefined hypotheses of the change score. Minimally important differences (MIDs) were calculated using anchor and distribution-based methods. Results: Of 166 eligible participants, 142 completed a baseline assessment and 79 (56%) and 55 (39%) completed the 3 and 6 month follow-ups, respectively. Mean age of study participants was 56 years (standard deviation = 19). Toenail conditions predominated (54%), with onychomycosis being the most common condition (54%). Hypothesis acceptance rates demonstrated validity of the change score for the Appearance 88% (15/17), Nail Symptoms 80% (16/20), and Outcome (treatment-related) 91% (10/11) scales. Effect sizes were moderate for Appearance, Nail Distress, and Outcome scales (0.6-0.7). MID values for the 3 scales ranged from 9 to 14. Conclusions: The NAIL-Q demonstrated sufficient evidence of responsiveness in patients undergoing treatment for nail psoriasis, onychomycosis, brittle nails, or retronychia.
- 18 March 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5) , 498-503
Open AccessResponsiveness of the NAIL-Q Patient-Reported Outcome Measure
Background: Nail conditions account for ~10% of dermatological conditions and can significantly impact quality of life. The NAIL-Q is a patient-reported outcome measure that was developed to measure outcomes that matter to patients treated for any type of fingernail or toenail condition. The ability of the NAIL-Q to detect change (ie, responsiveness) has not yet been established. Objective: To evaluate the responsiveness of the NAIL-Q in patients undergoing treatment for nail psoriasis, onychomycosis, brittle nails, and retronychia. Methods: This prospective validation study included patients newly diagnosed at an urban dermatology clinic in the United States. Participants completed the NAIL-Q at baseline, 3, and 6 months. Responsiveness was evaluated by testing predefined hypotheses of the change score. Minimally important differences (MIDs) were calculated using anchor and distribution-based methods. Results: Of 166 eligible participants, 142 completed a baseline assessment and 79 (56%) and 55 (39%) completed the 3 and 6 month follow-ups, respectively. Mean age of study participants was 56 years (standard deviation = 19). Toenail conditions predominated (54%), with onychomycosis being the most common condition (54%). Hypothesis acceptance rates demonstrated validity of the change score for the Appearance 88% (15/17), Nail Symptoms 80% (16/20), and Outcome (treatment-related) 91% (10/11) scales. Effect sizes were moderate for Appearance, Nail Distress, and Outcome scales (0.6-0.7). MID values for the 3 scales ranged from 9 to 14. Conclusions: The NAIL-Q demonstrated sufficient evidence of responsiveness in patients undergoing treatment for nail psoriasis, onychomycosis, brittle nails, or retronychia.
- 25 November 2025
- Published by SAGE Publications in Plastic Surgery
- Vol. 34 (1) , 5-8
Ethical Landmines in Aesthetic Surgery Research: Practical Considerations for Surgeon Researchers
- 25 November 2025
- Published by SAGE Publications in Plastic Surgery
- Vol. 34 (1) , 5-8
Ethical Landmines in Aesthetic Surgery Research: Practical Considerations for Surgeon Researchers
- 27 October 2025
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 47 (2) , 603-610
Predictors of Prolonged Length of Stay (LOS) in Adult and Elderly Burn Patients: A Retrospective Review of 2325 Patients
Increased length of stay (LOS) in patients with burn injuries is associated with increased adverse and poorer outcomes. Despite the awareness of the profound risks associated with increased LOS, large studies examining associated variables are lacking. This study aimed to identify pre-existing conditions, injury characteristics, and intrahospital events that influence whether patients meet or exceed the expected LOS based on the LOS:TBSA ratio, 1.5 days for adults aged 18-59 years and 2.0 days for older adults aged ≥ 60 years. A retrospective review of an adult cohort study admitted to a tertiary burn center was conducted. We included all surviving patients with burn injuries admitted from January 2006 to June 2021. Primary outcome was whether patients met or exceeded the expected LOS:TBSA ratio. Median (IQR) age was 45 (31-58) years, 1635 (70%) were male, and median (IQR) %TBSA was 7 (3-14). Median (IQR) LOS was 13 (6-20) days, and LOS:TBSA median (IQR) was 1.65 (0.98-2.95). We found inhalation injury to be a predictor of prolonged LOS in both adults and older adults, while female sex and greater age only contributed to increased LOS in the adult group. In-hospital complications are modifiable factors of prolonged LOS in both adults and older adult patients. We identified that greater age, female sex, inhalation injury along with in-hospital complications affected LOS in adults. Greater age and sex did not affect LOS in older adult patients. Identified risk factors should be adjusted for in future prospective studies.
- 27 October 2025
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 47 (2) , 603-610
Predictors of Prolonged Length of Stay (LOS) in Adult and Elderly Burn Patients: A Retrospective Review of 2325 Patients
Increased length of stay (LOS) in patients with burn injuries is associated with increased adverse and poorer outcomes. Despite the awareness of the profound risks associated with increased LOS, large studies examining associated variables are lacking. This study aimed to identify pre-existing conditions, injury characteristics, and intrahospital events that influence whether patients meet or exceed the expected LOS based on the LOS:TBSA ratio, 1.5 days for adults aged 18-59 years and 2.0 days for older adults aged ≥ 60 years. A retrospective review of an adult cohort study admitted to a tertiary burn center was conducted. We included all surviving patients with burn injuries admitted from January 2006 to June 2021. Primary outcome was whether patients met or exceeded the expected LOS:TBSA ratio. Median (IQR) age was 45 (31-58) years, 1635 (70%) were male, and median (IQR) %TBSA was 7 (3-14). Median (IQR) LOS was 13 (6-20) days, and LOS:TBSA median (IQR) was 1.65 (0.98-2.95). We found inhalation injury to be a predictor of prolonged LOS in both adults and older adults, while female sex and greater age only contributed to increased LOS in the adult group. In-hospital complications are modifiable factors of prolonged LOS in both adults and older adult patients. We identified that greater age, female sex, inhalation injury along with in-hospital complications affected LOS in adults. Greater age and sex did not affect LOS in older adult patients. Identified risk factors should be adjusted for in future prospective studies.
- Open Access
- 21 October 2025
- Published by SAGE Publications in Plastic Surgery
- Vol. 34 (4) , 660-669
The Impact of Breast Reduction Practice Variation in Hamilton, Ontario: A Cost Analysis
Introduction: Bilateral breast reduction (BBR) is one of the most common Ministry of Health-funded plastic surgery procedures. Surgeon variation in BBR management has been reported. In this study, we aimed to answer the following: what are the current variations in plastic surgeons’ management of BBR in Hamilton, Ontario?, and what are the cost implications of these practice variations to the healthcare system and patients? Methods: An online survey was conducted to gather demographic and practice data from all plastic surgeons practicing in Hamilton from 2019 to 2024. Reference costs for pre-, intra-, and postoperative components of BBR were obtained from a tertiary academic care center, the Ontario Schedule of Benefits for Physician Services, and local nursing care agencies, and used in the calculation of individual surgeons’ healthcare and patient costs. Results: Among 17 plastic surgeons practicing in Hamilton, 9 perform BBR, and 7 participated in the survey (response rate = 77.8%). Variations in practice were identified across several areas, including drain use, nursing care, OR time, and frequency of physician appointments. The mean healthcare costs per BBR patient were $5156 and $7146 for the lowest- and highest-costing surgeons, respectively, resulting in a difference of up to $2034 per patient. Patient-borne costs varied from $92 to $179 between surgical practices. Conclusion: There is considerable variability in BBR practice among plastic surgeons in Hamilton, contributing to a difference in overall healthcare and patient costs. Given the importance of cost savings in a single-payer system, future research is warranted to standardize BBR practices.
- 21 October 2025
- Published by SAGE Publications in Plastic Surgery
- Vol. 34 (4) , 660-669
Open AccessThe Impact of Breast Reduction Practice Variation in Hamilton, Ontario: A Cost Analysis
Introduction: Bilateral breast reduction (BBR) is one of the most common Ministry of Health-funded plastic surgery procedures. Surgeon variation in BBR management has been reported. In this study, we aimed to answer the following: what are the current variations in plastic surgeons’ management of BBR in Hamilton, Ontario?, and what are the cost implications of these practice variations to the healthcare system and patients? Methods: An online survey was conducted to gather demographic and practice data from all plastic surgeons practicing in Hamilton from 2019 to 2024. Reference costs for pre-, intra-, and postoperative components of BBR were obtained from a tertiary academic care center, the Ontario Schedule of Benefits for Physician Services, and local nursing care agencies, and used in the calculation of individual surgeons’ healthcare and patient costs. Results: Among 17 plastic surgeons practicing in Hamilton, 9 perform BBR, and 7 participated in the survey (response rate = 77.8%). Variations in practice were identified across several areas, including drain use, nursing care, OR time, and frequency of physician appointments. The mean healthcare costs per BBR patient were $5156 and $7146 for the lowest- and highest-costing surgeons, respectively, resulting in a difference of up to $2034 per patient. Patient-borne costs varied from $92 to $179 between surgical practices. Conclusion: There is considerable variability in BBR practice among plastic surgeons in Hamilton, contributing to a difference in overall healthcare and patient costs. Given the importance of cost savings in a single-payer system, future research is warranted to standardize BBR practices.
- Open Access
- 1 July 2025
- Published by SAGE Publications in Plastic Surgery
Closed-Incision Negative Pressure Therapy Compared to Conventional Dressing Following Autologous Abdominal Tissue Breast Reconstruction: The MACVAC Pilot Randomized Control Trial
Introduction: There is equipoise regarding the use of closed-incision negative pressure therapy (ciNPT) versus conventional dressings for abdominal incisions in deep inferior epigastric perforator (DIEP) flap breast reconstruction. The primary objective was to determine the feasibility of conducting a randomized controlled trial (RCT) comparing ciNPT versus conventional dressings for abdominal incisions in DIEP flap breast reconstruction. Methods: A parallel, between-group randomized controlled pilot trial was conducted at two academic breast reconstruction centers. Participants were included if they were adult female patients (≥18 years old) receiving immediate or delayed DIEP flap breast reconstruction. Participants were excluded if they were pregnant, had an allergy to adhesive dressings, or had a body mass index ≥40 kg/m 2 . Primary feasibility outcomes were attaining a 90% eligibility rate, 85% recruitment rate, and 85% retention rate. Secondary outcomes were abdominal site complications and patient-reported health-related quality of life measurements. Block randomization was performed in a 1:1 ratio intraoperatively following abdominal incision closure. Outcome assessment was performed by a blinded assessor. Results: There were 12 patients randomized to each group. The eligibility rate was 90.6%, recruitment rate was 86.2%, pre-randomization retention rate was 96.0%, and post-randomization retention rate was 95.8%. Wound dehiscence rates were 16.7% in the intervention and 41.7% in the control group. Conclusion: The full RCT was deemed feasible based on a priori feasibility outcomes. The anticipated sample size will be 54 patients per group to achieve adequate statistical power. The full multicenter trial is currently in the recruitment process. Trial Registration: NCT04985552.
- 1 July 2025
- Published by SAGE Publications in Plastic Surgery
Open AccessClosed-Incision Negative Pressure Therapy Compared to Conventional Dressing Following Autologous Abdominal Tissue Breast Reconstruction: The MACVAC Pilot Randomized Control Trial
Introduction: There is equipoise regarding the use of closed-incision negative pressure therapy (ciNPT) versus conventional dressings for abdominal incisions in deep inferior epigastric perforator (DIEP) flap breast reconstruction. The primary objective was to determine the feasibility of conducting a randomized controlled trial (RCT) comparing ciNPT versus conventional dressings for abdominal incisions in DIEP flap breast reconstruction. Methods: A parallel, between-group randomized controlled pilot trial was conducted at two academic breast reconstruction centers. Participants were included if they were adult female patients (≥18 years old) receiving immediate or delayed DIEP flap breast reconstruction. Participants were excluded if they were pregnant, had an allergy to adhesive dressings, or had a body mass index ≥40 kg/m 2 . Primary feasibility outcomes were attaining a 90% eligibility rate, 85% recruitment rate, and 85% retention rate. Secondary outcomes were abdominal site complications and patient-reported health-related quality of life measurements. Block randomization was performed in a 1:1 ratio intraoperatively following abdominal incision closure. Outcome assessment was performed by a blinded assessor. Results: There were 12 patients randomized to each group. The eligibility rate was 90.6%, recruitment rate was 86.2%, pre-randomization retention rate was 96.0%, and post-randomization retention rate was 95.8%. Wound dehiscence rates were 16.7% in the intervention and 41.7% in the control group. Conclusion: The full RCT was deemed feasible based on a priori feasibility outcomes. The anticipated sample size will be 54 patients per group to achieve adequate statistical power. The full multicenter trial is currently in the recruitment process. Trial Registration: NCT04985552.
- 28 June 2025
- Published by Springer Nature
- p. 177-190
The Surgeon’s Guide to Systematic Review and Meta-Analysis
- 28 June 2025
- Published by Springer Nature
- p. 177-190
The Surgeon’s Guide to Systematic Review and Meta-Analysis